TY  - JOUR 
AU  - Einsele, Hermann
AU  - Moreau, Philippe
AU  - Bahlis, Nizar
AU  - Bhutani, Manisha
AU  - Vincent, Laura
AU  - Karlin, Lionel
AU  - Perrot, Aurore
AU  - Goldschmidt, Hartmut
AU  - van de Donk, Niels
AU  - Ocio San Miguel, Enrique M.
AU  - Martínez López, Joaquín
AU  - Rodríguez Otero, Paula
AU  - Dytfeld, Dominik
AU  - Diels, Joris
AU  - Strulev, Vadim
AU  - Haddad, Imene
AU  - Renaud, Thomas
AU  - Ammann, Eric
AU  - Cabrieto, Jedelyn
AU  - Perualila, Nolen
AU  - Gan, Ryan
AU  - Zhang, Youyi
AU  - Parekh, Trilok
AU  - Albrecht, Claire
AU  - Weisel, Katja
AU  - Mateos Manteca, María Victoria
PY  - 2024
SN  - 0741-238X
UR  - http://hdl.handle.net/10366/166687
AB  - [EN] Introduction: Talquetamab, a bispecific antibody
targeting GPRC5D 9 CD3, is approved for
the treatment of patients with triple-class -
exposed (TCE) relapsed/refractory multiple
myeloma (RRMM) on the basis of the results
from the phase I/II...
LA  - eng
PB  - Springer
KW  - LocoMMotion
KW  - MoMMent
KW  - MonumenTAL-1
KW  - Talquetamab
KW  - Triple-class-exposed relapsed/refractory multiple myeloma
KW  - Multiple Myeloma
TI  - Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma
DO  - 10.1007/s12325-024-02797-x
T2  - Advances in Therapy
VL  - 41
M2  - 1576
ER  -